Watch MIST. Know when insiders buy.
One email the day a filing lands. Free.
MIST
Milestone Pharmaceuticals Inc.
0.69
−0.02 −3.34%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
40
WATCH · shorts 40
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $86.5MP/E —DIV YIELD —FCF YIELD -71.25%REV TTM —NET INCOME −$84MNET CASH $110.5M52W 0.69 – 2.95SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $559K | — | 94.3% | −$25.6M | −$28.6M | — | -0.21 | −$22.7M | $26K | −$22.7M | Aug 12 |
| Q1 2026 · Mar 31 | $238K | — | 94.1% | −$23.7M | −$26.1M | — | -0.20 | −$16.1M | $45K | −$16.1M | May 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$17.3M | −$17.4M | — | -0.15 | −$12.8M | $283K | −$13.1M | Mar 20 |
| Q3 2025 · Sep 30 | — | — | — | −$11.8M | −$11.9M | — | -0.12 | −$9.7M | $2K | −$9.8M | Nov 12 |
| Q2 2025 · Jun 30 | $0 | — | — | −$12.5M | −$13M | — | -0.20 | −$12.6M | $11K | −$12.6M | Aug 12 |
| Q1 2025 · Mar 31 | $0 | — | — | −$20.5M | −$20.8M | — | -0.31 | −$14M | $6K | −$14M | May 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$12.3M | −$12.4M | — | -0.19 | −$6.8M | $22K | −$6.9M | Mar 20 |
| Q3 2024 · Sep 30 | — | — | — | −$9.6M | −$9.4M | — | -0.14 | −$7M | $4K | −$7M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$9.7M | −$9.4M | — | -0.14 | −$6.1M | — | — | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$10.5M | −$10.4M | — | -0.21 | −$8.9M | — | — | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$13.8M | −$13.6M | — | -0.32 | −$9.8M | $31K | −$9.8M | Mar 13 |
| Q3 2023 · Sep 30 | — | — | — | −$15.4M | −$15.1M | — | -0.35 | −$12.2M | $18K | −$12.2M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$62.1M | −$63.1M | — | -0.75 | −$49M | $302K | −$49.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$42.1M | −$41.5M | — | -0.67 | −$28.8M | $33K | −$28.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$61.1M | −$59.7M | — | -1.39 | −$46.4M | $112K | −$46.5M | — | — |
| FY2022 · to Dec 31 | — | — | −$59.6M | −$58.4M | — | -1.38 | −$52.5M | $272K | −$52.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$43.1M | −$42.9M | — | -1.02 | −$33.2M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$50.7M | −$50M | — | -1.70 | −$50.7M | — | — | — | — |
Every number comes from Milestone Pharmaceuticals Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.